文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

针对HIV感染重症肺炎婴儿的巨细胞病毒和结核病经验性治疗:多中心、开放标签、随机对照临床试验的研究方案

Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial.
PubMed 文献 · Trials · 2022-06-27

本研究为在六个非洲国家开展的多中心、开放标签、随机析因(2×2)II-III期临床试验,纳入28至365日龄的HIV感染且因重症肺炎住院的婴儿,按1:1:1:1随机分为标准治疗组、缬更昔洛韦组、结核经验性治疗组及结核经验性治疗联合缬更昔洛韦组,主要终点为15天内和1年内的全因死亡率。

要点

  • 研究比较经验性抗结核和抗巨细胞病毒治疗联合标准治疗与单纯标准治疗对HIV感染重症肺炎婴儿15天及1年死亡率的影响。
  • 试验设四组:标准治疗、缬更昔洛韦、结核经验性治疗、结核经验性治疗联合缬更昔洛韦。
  • 次要终点包括再住院、氧疗时长、不良事件、巨细胞病毒和结核患病率及诊断检测评估。

核心结论

  • 研究旨在评估对HIV感染重症肺炎婴儿进行巨细胞病毒和结核经验性治疗的新方法。

研究设计与样本

  • 多中心、开放标签、随机析因(2×2)II-III期临床试验,在六个非洲国家开展。
  • 纳入28至365日龄的HIV感染且因重症肺炎住院的婴儿,按1:1:1:1随机分为四组。
  • 四组分别为标准治疗、缬更昔洛韦、结核经验性治疗、结核经验性治疗联合缬更昔洛韦。

关键数值与推荐

  • 主要终点为全因死亡率,重点关注短期(至15天)和长期(至1年)死亡率。
  • 次要终点包括再住院、初次住院期间氧疗时长、严重和值得注意的不良事件、不良药物反应、入组时巨细胞病毒和结核患病率、结核发病率、巨细胞病毒载量下降及诊断检测评估。
  • 诊断检测评估包括粪便和鼻咽 aspirate 样本的GeneXpert Ultra及尿TB-LAM。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 经验性治疗这些疾病的潜在缺点包括毒性和药物相互作用,将通过药代动力学子研究进行评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumonia is the primary cause of death among HIV-infected children in Africa, with mortality rates as high as 35-40% in infants hospitalized with severe pneumonia. Bacterial pathogens and Pneumocystis jirovecii are well known causes of pneumonia-related death, but other important causes such as cytomegalovirus (CMV) and tuberculosis (TB) remain under-recognized and undertreated. The immune response elicited by CMV may be associated with the risk of developing TB and TB disease progression, and CMV may accelerate disease caused both by HIV and TB. Minimally invasive autopsies confirm that CMV and TB are unrecognized causes of death in children with HIV. CMV and TB may also co-infect the same child. The aim of this study is to compare the impact on 15-day and 1-year mortality of empirical treatment against TB and CMV plus standard of care (SoC) versus SoC in HIV-infected infants with severe pneumonia. METHODS: This is a Phase II-III, open-label randomized factorial (2 × 2) clinical trial, conducted in six African countries. The trial has four arms. Infants from 28 to 365 days of age HIV-infected and hospitalized with severe pneumonia will be randomized (1:1:1:1) to (i) SoC, (ii) valganciclovir, (iii) TB-T, and (iv) TB-T plus valganciclovir. The primary endpoint of the study is all-cause mortality, focusing on the short-term (up to 15 days) and long-term (up to 1 year) mortality. Secondary endpoints include repeat hospitalization, duration of oxygen therapy during initial admission, severe and notable adverse events, adverse reactions, CMV and TB prevalence at enrolment, TB incidence, CMV viral load reduction, and evaluation of diagnostic tests such as GeneXpert Ultra on fecal and nasopharyngeal aspirate samples and urine TB-LAM. DISCUSSION: Given the challenges in diagnosing CMV and TB in children and results from previous autopsy studies that show high rates of poly-infection in HIV-infected infants with respiratory disease, this study aims to evaluate a new approach including empirical treatment of CMV and TB for this patient population. The potential downsides of empirical treatment of these conditions include toxicity and medication interactions, which will be evaluated with pharmacokinetics sub-studies. TRIAL REGISTRATION: ClinicalTrials.gov , NCT03915366, Universal Trial Number U111-1231-4736, Pan African Clinical Trial Registry PACTR201994797961340.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rojo P, Moraleda C, Tagarro A, et al. Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial. Trials. 2022. PMID: 35761406. doi:10.1186/s13063-022-06203-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。